Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BTLA/CD272 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BTLA/CD272 ECD-Fc Fusion Protein (Human, Mutant available). High purity (>95%), Endotoxin <1EU/μg. Sequence Verified. HEK293 expressed for native glycosylation. | View BTLA Products |
| Ligand Control | HVEM/TNFRSF14 ECD-Fc Protein. Critical binding partner for competitive assays. SPR-validated binding pair available. | View HVEM Products |
| Gene Delivery | BTLA Lentivirus Premade Particles. Full-length ORF for stable cell line construction. High titer (>10^8 TU/mL). | View BTLA Products |
| Benchmark Ab | Anti-BTLA Reference Antibody (sequence of Tifcemalimab). Recombinant positive control matching clinical competitor sequences. | View BTLA Products |
| Validator | BTLA siRNA Set. For knockdown specificity verification. Sequence-verified. | View BTLA Products |
| Related Target A | PD-1/PDCD1. Primary combination target in clinical trials. Synergistic checkpoint blockade. | View PD-1 Products |
| Related Target B | CD160. Competitive HVEM binder. Alternative inhibitory pathway for counter-screening. | View CD160 Products |
Critical Assay Challenges and TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species ortholog evaluation (cyno/mouse/human) | Ortholog protein panel available: Human, Cynomolgus, and Mouse BTLA ECD-Fc. Sequence verified by mass spec, >95% purity. |
| Ligand competition (HVEM binding blockade) | High-affinity HVEM-Fc provided as positive control. SPR-validated binding pair available. |
| Native glycosylation and conformational integrity | HEK293 expressed proteins with native human glycosylation. Lentivirus particles for stable overexpression cell lines preserving native folding. |
| False positive screening and specificity control | Validated siRNA set for knockdown verification. Clinical Benchmark Antibodies included for assay control. |
Global Clinical Landscape & Future Outlook
The BTLA/HVEM axis represents a next-generation immune checkpoint pathway distinct from the exhausted T cell markers. As PD-1/PD-L1 inhibitors face resistance limitations in solid tumors, BTLA blockade is emerging as a critical combinatorial strategy to restore T cell functionality in the tumor microenvironment. The race for BTLA therapeutics is intensifying, with major players exploring both antagonistic monoclonal antibodies for oncology and agonistic approaches for autoimmune conditions. Current development focuses on overcoming primary resistance in non-T cell-inflamed tumors through dual checkpoint inhibition, while bispecific modalities (e.g., PD-1×BTLA) and combination strategies are the next wave of R&D to overcome resistance pathways seen in early checkpoint inhibitor trials.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antagonistic Monoclonal Antibody | Bristol Myers Squibb, Novartis, Agenus, Junshi Biosciences, Hanmi | Solid Tumors (NSCLC, Melanoma), Lymphoma | Binding/Blocking Assays (Need high-purity BTLA ECD-Fc & HVEM) |
| Agonistic Monoclonal Antibody | Eli Lilly, AnaptysBio | Autoimmune Diseases (SLE, RA) | Receptor Activation (Need stable cell lines for signaling evaluation) |
| Bispecific (e.g., PD-1×BTLA) | OncoC4, I-Mab, Innovent Biologics | Immunotherapy-refractory cancers | Dual binding validation (Need high-purity dual targets and cross-reactive orthologs) |
| Fusion Protein | Early stage biotechs | Autoimmune diseases | Stability testing (Need high-concentration protein formulations) |
Live BTLA/CD272 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: